Determinants of metabolic dysfunction associated steatotic liver disease and liver fibrosis in patients with type 2 diabetes mellitus: a cross-sectional study - Report - MDSpire
Advertisement
Determinants of metabolic dysfunction associated steatotic liver disease and liver fibrosis in patients with type 2 diabetes mellitus: a cross-sectional study
This study identifies the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with type 2 diabetes mellitus (T2D) and highlights factors associated with advanced liver fibrosis. The findings indicate that 69.1% of participants met the criteria for MASLD, with 17.4% unable to rule out advanced fibrosis.
Background
MASLD is the leading cause of chronic liver disease globally, particularly in the context of rising obesity and metabolic disorders. The condition is closely linked to type 2 diabetes, with a significant prevalence among diabetic patients.
Data Highlights
Measure
Value
Average Age
57.9 ± 11.8 years
Female Predominance
63.8%
MASLD Prevalence
69.1% [95% CI (61.7–76.5)]
Advanced Fibrosis Risk
17.4% [95% CI (11.7-24.5)]
Median Liver Stiffness
5.0 kPa (IQR 4.0–6.5)
Key Findings
69.1% of patients with T2D met the criteria for MASLD.
Advanced fibrosis could not be ruled out in 17.4% of patients.
High Body Mass Index (aOR = 1.25) and total cholesterol (aOR = 1.69) are independent predictors of MASLD.
Higher platelet distribution width (PDW) is associated with nearly a threefold increase in the odds of advanced fibrosis (aOR = 2.78).
Healthcare providers should be aware of the high prevalence of MASLD in patients with T2D and the associated risk of advanced fibrosis. Regular screening and monitoring for liver disease in this population are essential for timely intervention.
Conclusion
The study underscores the importance of identifying patients with MASLD and advanced fibrosis to implement appropriate management strategies and prevent severe liver complications.
